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Microarrays  have  proven  to be useful  in  rapid  detection  of  many  viruses  and  bacteria.  Pathogen  detection
microarrays  have  been  used  to diagnose  viral  and  bacterial  infections  in clinical  samples  and  to evalu-
ate  the  safety  of biological  drug  materials.  A multiplexed  version  of  the  Lawrence  Livermore  Microbial
Detection  Array  (LLMDA)  was  developed  and  evaluated  with  minimum  detectable  concentrations  for  pure
unampliﬁed  DNA  viruses,  along  with  mixtures  of  viral  and  bacterial  DNA subjected  to  different  whole
genome  ampliﬁcation  protocols.  In addition  the performance  of  the  array  was  tested  when  hybridization
time  was  reduced  from  17 h to 1  h. The  LLMDA  was  able  to detect  unampliﬁed  vaccinia  virus  DNA  at  a
concentration  of  14  fM, or  100,000  genome  copies  in 12  L  of sample.  With  ampliﬁcation,  positive  iden-
tiﬁcation  was  made  with  only  100  genome  copies  of  input  material.  When  tested  against  human  stool
samples  from  patients  with  acute  gastroenteritis,  the microarray  detected  common  gastroenteritis  viral
and bacterial  infections  such  as  rotavirus  and  E.  coli.
Accurate  detection  was  found  but with  a 4-fold  drop  in sensitivity  for a 1 h  compared  to  a 17 h hybridiza-
tion.  The  array  detected  2 ng (equivalent  concentration  of 15.6  fM)  of  labeled  DNA  from  a virus  with  1  h
hybridization  without  any  ampliﬁcation,  and was  able  to  identify  the  components  of a mixture  of  viruses
and  bacteria  at species  and  in  some  cases  strain  level  resolution.  Sensitivity  improved  by  three  orders
of  magnitude  with  random  whole  genome  ampliﬁcation  prior  to  hybridization;  for  instance,  the  array
detected  a  DNA  virus  with  only  20 fg  or 100  genome  copies  as  input.  This multiplexed  microarray  is
an  efﬁcient  tool  to analyze  clinical  and  environmental  samples  for the  presence  of  multiple  viral  and
bacterial  pathogens  rapidly.
 2014©
. Introduction
Rapid detection and characterization of bacterial and viral
athogens is important for clinical microbiological diagnostics,
ublic health, drug and food safety, environmental monitoring and
iodefense. Various detection technologies based on nucleic acid
ignatures have emerged in the past few years, including TaqMan
CR and Luminex bead based systems. While these technologies
re able to identify selected pathogens at the species or strain
evel rapidly, they do not have the capability to provide broad
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spectrum detection about known or novel organisms. Character-
ization of known, emerging, engineered, or unknown pathogens
requires a platform that has the capacity to assess whole genome
sequence content from a variety of pathogens very rapidly. While
sequencing provides the most in depth information to charac-
terize a microbial genome, the costs, labor, and time associated
with library preparation, sequencing, bioinformatic analysis, and
data storage may  be prohibitive when analyzing many iso-
lates in a standard laboratory setting. To meet this need, a
pan-microbial microarray was developed, the Lawrence Liver-
more Microbial Detection Array (LLMDA) (Gardner et al., 2010).
The original version of this array contains 388,000 probes cov-
ering all currently sequenced viruses and bacteria, and can
detect any of these organisms within 24 h. This microarray
uses long (50–65 bp) oligonucleotide probes to enable detec-
Open access under CC BY-NC-ND license.tion of novel, divergent species with homology to sequenced
organisms. The LLMDA has been recently used to identify a con-
taminating pig virus from a rotavirus vaccine (Victoria et al.,
2010), a vaccine used worldwide in infants to prevent rotavirus
 license.
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Table  1
Probe summary for 72 K LLMDA array.
Number of
probes
Average
number of
probes per
sequence
Target sequences
48,893 20 All viral families except
Orthomyxoviridae and family
unclassiﬁed complete viral genomes
and segments
7777 10 Segments in the Orthomyxoviridae
family
2972 10 Family unclassiﬁed viral genomes and
complete segments
7864 15 Bacterial genomes and plasmids
3410 – Random controls with GC% and length
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rdistribution matched to target probes
70,916 Total
nfection. This array has also been used to detect viral infec-
ions from various human clinical samples (Erlandsson et al.,
011).
Recent development of multiplexed microarrays makes
creening of large numbers of samples more cost-effective with
igher throughput (Palka-Santini et al., 2009; Suo et al., 2010;
ierbaum et al., 2012). These multiplexed microarrays are low
o medium density and are focused on a relatively small number
f pathogens. A modiﬁed version of the LLMDA was  developed,
sing the 4 × 72 K Roche NimbleGen microarray format that
ould serve as a broad spectrum and fast detection technology to
nalyze bacterial and viral pathogens. This array contains a total of
0,916 probes, designed to detect 2200 viral species (38,000 target
equences) and 900 bacterial species (3500 target sequences).
 target was deﬁned as a separately accessioned draft genome,
nished chromosome, plasmid or viral segment sequenced.
A series of experiments with the 4 × 72 K array was  performed to
stimate the minimum detectable concentrations of pure viral tem-
lates and mixtures of viral and bacterial templates, both with and
ithout ampliﬁcation, using various random ampliﬁcation tech-
iques. The sensitivity and speciﬁcity of the microarray was  also
xplored when it was hybridized for much shorter times than the
tandard 17 h. In addition the array was tested using known and
nknown clinical samples to evaluate its utility in detecting infec-
ious agents from human samples.
. Materials and methods
.1. Probe design for the 4 × 72 K LLMDA array
Probe design for the 388 K version of the Lawrence Livermore
icrobial Detection Array (LLMDA) was described in Gardner et al.
Gardner et al., 2010). For the 4 × 72 K version, the initial pool
f candidate probes was down-selected to have a total of 70,916
robes, as indicated in Table 1, rather than the 388,000 probes
elected for the previous version. Each viral genome or segment
arget was represented by 10–20 probes on the 72 K array, in con-
rast to the 50 probes per target in the 388 K version. The same
rocess was used to down-select from the candidate pool of oli-
os as was described in (Gardner et al., 2010). The same bacterial
robes were used as on the 388 K version, with 15 probes per tar-
et. The arrays were custom ordered using the 4-plex 72 K format
rom Roche NimbleGen..2. Nucleic acid extraction from bacterial and viral samples
Human adenovirus type 7 strain Gomen (Adenoviridae) and
espiratory syncytial virus (RSV) were purchased from the Nationalal Methods 201 (2014) 73–78
Veterinary Services Laboratory (Ames, IA) and grown at Lawrence
Livermore National Laboratory (LLNL). For puriﬁcation of adenovi-
rus DNA, a solution of 10 mL  virus culture, 1 mL  5.5% Triton X-100,
and 460 L 0.5 M EDTA was  added to a 50 mL  tube and vortexed vig-
orously. Following vortexing, 1.28 mL  10% SDS and 540 L 10 U/mL
proteinase K was  added to the mixture and incubated at 55 ◦C for 1 h
with mixing every 10 min. After incubation, 420 L 5 M NaCl and
13.7 mL  25:24:1 phenol/chloroform/isoamyl alcohol was  added to
the tube and inverted until the mixture was completely homoge-
nous. Once homogenous, the solution was  centrifuged at 10,000 × g
for 10 min  and the upper aqueous layer was  transferred to a new
tube. A total of 27.4 mL  of 100% ethanol was  added to the aque-
ous layer and incubated at −20 ◦C for 1 h. Following incubation,
the solution was centrifuged at maximum speed for 10 min  and
the supernatant was discarded. The pellet was  washed once with a
solution of 70% ethanol and 150 mM NaCl. The liquid was removed
and pellet was  allowed to air dry before being re-suspended in
nuclease free water.
For extraction of RNA from RSV virus, a solution of 2 mL of virus
culture and 6 mL  TRIzol LS Reagent from Life Technologies was
mixed vigorously and incubated 15 min at room temperature. Fol-
lowing incubation, 1.6 mL  chloroform was  added to the cap of the
tube, shaken vigorously for 15 s, and incubated at room tempera-
ture for 15 min. The solution was  centrifuged at 4 ◦C for 15 min at
3000 × g and the aqueous layer was transferred to a new tube. 70%
isopropyl alcohol was  added to the aqueous layer, mixed by invert-
ing several times, and incubated for 10 min  at room temperature.
The solution was centrifuged at maximum speed for 10 min  at 4 ◦C
and the liquid was carefully poured off. The remaining pellet was
washed with 70% ice cold ethanol. The ethanol was poured off and
the pellet was air dried before being re-suspended in RNase free
water.
Ebola Zaire 95 and Rift Valley fever (RVF) virus strain ZH501
RNA were obtained from National Bioforensic Analysis and Coun-
termeasures Center (NBACC). Copy number quantitated vaccinia
Lister DNA was purchased through Advanced Biotechnologies Inc.
(Columbia, MD). Bacillus anthracis Ames DNA was obtained from
internal sources at Lawrence Livermore National Laboratory (LLNL)
and nucleic acids were extracted using the Epicentre DNA extrac-
tion kit according to manufacturer’s protocols.
Extracted nucleic acid samples from four pediatric stool samples
from children with acute gastroenteritis and enrolled in the New
Vaccine Surveillance Network (NVSN) were provided by Dr. Mike
Bowen from the Centers for Disease Control and Prevention (CDC).
2.3. Nucleic acid ampliﬁcation
The nucleic acid samples were ampliﬁed using four different
protocols: a protocol developed by Wang et al., 2003, referred
to in this study as Random PCR 1; the same protocol with mod-
iﬁed primers (Wong et al., 2007), referred to as Random PCR
2; the TransPlex® Whole Transcriptome Ampliﬁcation Kit (Cat.
WTA1) from Sigma Aldrich (St. Louis, MO)  (Iscove et al., 2002);
and QuantiTect Whole Transcriptome Kit (Cat. 207043) from Qia-
gen (Valencia, CA) (Berthet et al., 2008; Erlandsson et al., 2011).
One ng of Ebola Zaire 95 (9.34 × 107 genome copies) RNA,1 ng of
vaccinia Lister (4.76 × 106 genome copies) DNA, 1 ng of B. anthracis
Ames (1.77 × 105 genome copies) DNA and 1 ng of RVF (1.48 × 108
genome copies) RNA were mixed and the mixture was  ampliﬁed
using the four protocols respectively.
2.4. Sample preparation for limit of detection testingVaccinia Lister DNA was  10-fold serially diluted from
100,000 copies to 100 copies for limit of detection testing without
any whole genome ampliﬁcation. The Vaccinia Lister viral DNA was
rological Methods 201 (2014) 73–78 75
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Table 2
Microarray analysis of a mixture of viral and bacterial templates after different
random ampliﬁcation protocols.
Ampliﬁcation method Detected viruses and bacteria Log-odds score
Random PCR 1 Bacillus anthracis 474.5
Cowpox virus 216.5
Variola virus 15.0
RVF virus 126.2
Ebola Zaire 95 111.1
Random PCR 2 Bacillus anthracis 473.3
Vaccinia virus 210.3
Variola virus 13.6
RVF virus 124.9
Ebola Zaire 95 110.0
Sigma TransPlex Bacillus cereus 132.9
Vaccinia virus 223.1
Variola virus 18.8
RVF virus 136.6
Ebola Zaire 95 115.4
Qiagen WTA Bacillus anthracis 504.1
Cowpox virus 229.8
Variola virus 17.2
RVF virus 137.2
Ebola Zaire 95 109.8
Results from the microarray data were analyzed using the composite likelihood
maximization method. The conditional log-odds scores for the samples are shown.
The log likelihood is estimated from the BLAST similarity scores of the probes to each
of  the possible target sequences, together with the probe sequence complexity andJ.B. Thissen et al. / Journal of Vi
lso 10-fold serially diluted from 10,000 copies to 10 copies and
mpliﬁed using the Random PCR 2 protocol, and the entire ampli-
ed product was hybridized to the array. Copy number quantitation
as performed by the Advanced Biotechnologies Inc. (Columbia,
D)  by real time PCR using the Roche LightCycler.
RSV was titered at LLNL and tissue culture infectious dose 50
TCID50) was determined. The viral RNA was 10-fold serially diluted
rom 1,000,000 TCID50 to 1000 TCID50 and reverse transcribed
nto cDNA. Double-stranded cDNA was synthesized according to
he Invitrogen SuperScript® Double-Stranded cDNA Synthesis Kit
nstructions. RSV RNA was also 10 fold serially diluted from 100
CID50 to 0.1 TCID50 and ampliﬁed using Random PCR 2 ampliﬁ-
ation. The entire ampliﬁed product was labeled and hybridized to
he 4-plex arrays.
.5. Sample labeling and microarray hybridization
The 72 K 4-plex DNA microarrays were synthesized by Roche
imbleGen. Four different samples can be run on each of the subar-
ays simultaneously to save time and cost. Ampliﬁed or unampliﬁed
NA or cDNA samples were ﬂuorescently labeled using the Roche
imbleGen One-Color DNA Labeling Kit according to the recom-
ended protocols. The labeled sample was puriﬁed after labeling,
nd hybridized using the NimbleGen Hybridization Kit to the 4-plex
2 K array according to manufacturer’s instructions.
For limit of detection of adenovirus Gomen strain DNA, the
oncentration of ﬂuorescently labeled DNA was measured with a
ubit ﬂuorometer and the number of nanograms/genome equiva-
ent was determined based on GenBank chromosomal and plasmid
enome sizes. The input quantity to the labeling reaction was
50 ng (6.52 × 109 copies). Following labeling, approximately 16 g
4.16 × 1011 copies) of Cy3-labeled DNA was obtained. The labeled
ample was serially diluted 2 fold from 2 g (5.22 × 1010 copies) to
.5 ng (1.3 × 107 copies) and hybridized to the arrays.
The microarrays were allowed to hybridize for 17 h or 1 h at
2 ◦C, and washed using the NimbleGen Wash Buffer Kit (Cat.
5584507001) as described (Gardner et al., 2010). Microarrays
ere scanned on an Axon GenePix 4000B 5 M scanner from
olecular Devices (Sunnyvale, CA).
.6. Microarray data analysis
Microarray data were analyzed using the Composite Likelihood
aximization method (CLiMax) as described (Gardner et al., 2010).
he target database for the 4-plex 72 K array was built at a later
ate than that used for the 388 K version of the LLMDA; in all other
espects, the analysis was the same as reported (Gardner et al.,
010). Probes with signal intensity above the 99th percentile of
he random control intensities were considered positive, for the
urpose of data analysis.
. Results
.1. Comparison of different protocols to amplify a mixture of
athogens
Four different random ampliﬁcation protocols were performed
n a mixture of bacterial and viral nucleic acids, containing DNA
r RNA from B. anthracis Ames, Rift Valley fever virus strain ZH501,
accinia virus strain Lister, and Ebola virus strain Zaire 95, to evalu-
te the efﬁciencies of the different protocols. All four ampliﬁcation
roducts were correctly detected by microarray to the species level
Table 2). The log likelihood is estimated from the BLAST similar-
ty scores of the probes to each of the possible target sequences,
ogether with the probe sequence complexity and other covariates
erived from the BLAST results. Ebola virus Zaire 95 was  detectedother covariates derived from the BLAST results. A detailed list of detected target
sequences is provided in Supplementary File 1.
at the strain level. All three segments, S, L and M of the RVF genome
were detected on arrays using all four methods. Random PCR 1 and
2 and the Qiagen WTA  kit detected the B. anthracis chromosome
at the species level. Array analysis of the Sigma TransPlex prod-
uct gave a higher score to a strain of the closely related B. cereus
species rather than to B. anthracis. Orthopoxviruses were correctly
detected by all four arrays; the Random PCR 2 and Sigma TransPlex
arrays correctly identiﬁed vaccinia virus as the top scoring species,
while the Random PCR 1 and Qiagen WTA  arrays identiﬁed cowpox
virus as the top hit. All four arrays assigned a higher explanatory
score to a mixture of vaccinia or cowpox with variola virus than
to vaccinia or cowpox alone. Of the four protocols tested, Random
PCR 2 performed slightly better in terms of accuracy. In this study,
the Random PCR 2 protocol was  used to determine the detection
limit of ampliﬁed pathogens on the microarray.
3.2. Detection sensitivity of vaccinia virus
Vaccinia virus Lister DNA quantities of 100, 1000, 10,000 and
100,000 genome copies per 12 L sample volume were applied to
the 4 × 72 K array to analyze its limit of detection. Table 3 shows
the fraction of probes speciﬁc to vaccinia virus Lister strain that
had intensities greater than the 99th percentile of the negative
controls at different viral concentrations. Two independent biolog-
ical replicate experiments were performed. The average of the two
replicates resulted in more than 70% of the probes being above the
detection threshold at 100,000 copies of viral DNA, or a concentra-
tion of 14 fM.
Vaccinia virus Lister DNA quantities of 10, 100, 1000 and 10,000
genome copies were ampliﬁed using the Random PCR 2 method,
and the ampliﬁcation products were hybridized to the 4 × 72 K
MDA  array in order to analyze its limit of detection when com-
bined with PCR ampliﬁcation. Two replicate experiments were
performed. The array was  able to detect vaccinia Lister strain with
only 100 genome copies as input, with 72 and 82% of vaccinia-
speciﬁc probes detected for the two  replicates.
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Table  3
Detection of unampliﬁed and ampliﬁed Vaccinia Lister viral DNA on the 72 K LLMDA array.
Vaccinia virus Non ampliﬁed Ampliﬁed
DNA copy number in reaction 100 1000 10,000 100,000 10 100 1000 10,000
% of Vaccinia Lister strain probes detected in
each replicate
0% 0% 0% 79% 5% 82% 100% 100%
0%  0% 20% 68% 14% 72% 100% 100%
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yhe sensitivity of the array at different Vaccinia Lister virus DNA concentrations was
etected on the array. Two replicate experiments were performed and the percenta
.3. Detection sensitivity of RSV
RSV cDNA quantities of 1000, 10,000, 100,000 and 1,000,000
CID50 per 12 L sample volume were applied to the 4 × 72 K
rray. Table 4 shows the response of the array at different RSV
oncentrations. Two replicate experiments were performed. The
rray was able to detect RSV cDNA at 100,000 TCID50, with an aver-
ge of 90% of RSV-speciﬁc probes above the detection threshold.
RSV cDNA quantities of 0.1, 1, 10 and 100 TCID50 were ampliﬁed
y random PCR and applied to the 4 × 72 K MDA  array. Two  replicate
xperiments were performed. The array detected RSV cDNA from
he product of 1 TCID50, with an average of 75% of probes above the
etection threshold.
.4. Detection of adenovirus after 1 h and 17 h hybridization
After labeling human adenovirus type 7 Gomen strain DNA, 2-
old serial dilutions of the labeled DNA were performed from 2 g
o 0.5 ng and the diluted DNA was hybridized to the arrays for 17 h.
he DNA concentrations thus ranged from 3.9 fM to 15.6 pM.  The
esponse of the array to the adenovirus is shown in Table 5. At all
oncentrations tested, 90–100% of the probes speciﬁc to the ade-
ovirus strain tested were above the detection threshold. CLiMax
nalysis of these arrays identiﬁed the type 7 Gomen strain as the
op hit at all concentrations except the smallest (3.9 fM), at which
denovirus type 3 strain NHRC 1276 received the highest score.
To determine the speed of detection using this microarray,
ybridizations of adenovirus type 7 Gomen strain DNA were also
erformed for only 1 h. Serially diluted DNA quantities ranging
rom 2 g to 0.5 ng of DNA were hybridized to the array. Over
0% of the speciﬁc probes were above the threshold with 2 ng of
NA, corresponding to 15.6 fM concentration. CLiMax analysis pos-
tively identiﬁed the adenovirus type 7 Gomen strain with 8 ng of
NA after 1 h hybridization, compared to 1 ng of DNA with 17 h
ybridization.
.5. Detection of viruses and bacteria from human fecal samples
Four acute gastroenteritis samples received from the CDC’s
VSN were analyzed on the 72 K 4-plex microarray. These sam-
les were previously analyzed using enzyme immunoassays (EIA)
r real-time reverse transcription (RT)-PCR to determine the
resence of a limited number of known enteric pathogens (Bowen,
npublished results). Sample 4496 was negative by EIA or PCR
ssays. Rotavirus was detected in samples 4551, 4912 and 4949
sing EIA or PCR assays. Table 6 is a summary of the viruses
nd bacteria detected on the microarray. Rotavirus from sample
551 was not detected when all target sequences were used for
nalysis, but it was detected when viral target sequence database
nly was used in the analysis. For sample 4949, rotavirus was
etected in both replicates when viral target sequence database
nly was used in the analysis, however only one of two replicates
etected rotavirus when all target sequences were used in the anal-
sis.lated using the percentage of probes speciﬁc to Vaccinia Lister strain virus that were
tected out of 39 Vaccinia Lister strain speciﬁc probes is reported for each replicate.
The microarray results conﬁrmed the rotavirus ﬁndings from
the three samples that were previously tested positive for rotavirus
at the CDC. The microarray also detected a human calicivirus that
was not previously detected by PCR or EIA at the CDC. Additionally,
various bacterial pathogens including E. coli F11, Salmonella enter-
ica Typhi, Enterococcus faecium, Enterococcus faecalis, Bacteriodes
intestinalis were detected from the four samples. These bacteria
often cause nosocomial infections, gastrointestinal problems or uri-
nary tract infections.
4. Discussion
Microarrays, along with PCR and DNA sequencing are effective
methods for microbial detection and discovery using nucleic acid
samples. While microarrays are not as sensitive or inexpensive as
PCR assays, they can query hundreds of thousands to several mil-
lion regions of DNA in parallel (depending on platform and format),
compared to at most a few tens of regions in the largest multiplexed
PCR assays. PCR assays are too limited for broad-spectrum micro-
bial analysis. Several groups have applied microarray technology
to pathogen detection for clinical diagnostics, food safety test-
ing, environmental monitoring and biodefense (Wang et al., 2002;
Palacios et al., 2007; Wong et al., 2007; Palka-Santini et al., 2009;
Jaing et al., 2011; McLoughlin, 2011). One main limitation for the
wider use of pathogen detection microarrays is the cost of the assay,
which is at least an order of magnitude higher than PCR assays.
A multiplexed pathogen detection microarray was developed and
was a modiﬁed version of the previously reported Lawrence Liver-
more Microbial Detection Array (LLMDA) (Gardner et al., 2010) to
further improve the efﬁciency, cost-effectiveness and throughout
of pathogen detection microarrays.
In this study, four different ampliﬁcation protocols were ana-
lyzed: two  random PCR based protocols; the Qiagen whole
transcription ampliﬁcation protocol, which uses a phi29 DNA poly-
merase based approach; and the Sigma TransPlex kit, which also
uses PCR based ampliﬁcation. When four different protocols were
applied to a mixture of four viral and bacterial pathogens, RVF
and Ebola viruses were correctly identiﬁed at species resolution
by all protocols, B. anthracis was  correctly identiﬁed by two proto-
cols, Vaccinia virus was correctly identiﬁed by two  protocols. The
Random PCR 2 ampliﬁcation protocol correctly identiﬁed all four
species.
The detection limit of the array was evaluated by using serial
dilutions of a DNA virus, vaccinia virus Lister, and an RNA virus,
RSV, with various methods used to quantify the amounts of viral
DNA or RNA. Without whole genome ampliﬁcation, the detec-
tion limit for RSV is 100,000 TCID50. This is similar in range to
other molecular assays such as the real time PCR assay, multiplex
ligation-dependent probe ampliﬁcation (MLPA) and a dual prim-
ing oligonucleotide system (DPO) where the lowest concentration
detected for RSV was  105 TCID50 (Bruijnesteijn van Coppenraet
et al., 2010). For vaccinia virus Lister DNA without random ampli-
ﬁcation, the array detected 100,000 genome copies or about 20 pg
of viral DNA in the 12 L sample volume, corresponding to 14 fM
in concentration.
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Table  4
Detection of unampliﬁed and ampliﬁed RSV cDNA on the 72 K LLMDA array.
RSV Non ampliﬁed Ampliﬁed
TCID50 values in reaction 1000 10,000 100,000 1,000,000 0.1 1 10 100
% of RSV probes detected in each replicate 5% 9% 91% 100% 40% 73% 100% 100%
5%  11% 89% 100% 40% 77% 100% 100%
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the sensitivity of the array to detect RSV virus cDNA at different RSV TCID50 conce
etected on the array. Two  replicate experiments were performed and the percenta
The limit of detection for vaccinia virus DNA was found to be
00 copies when random whole genome ampliﬁcation was  used.
his detection limit is similar in range to PCR based technolo-
ies. A study using real time PCR assays to identify variants of
accinia virus detected the virus at 10 fg or around 50 genome
opies of vaccinia DNA (Trindade et al., 2008). The difference
n sensitivity between PCR and microarrays is partially due to
he random ampliﬁcation, using random primers, instead of a
iral speciﬁc PCR ampliﬁcation. Palka-Santini et al. has reported
hat speciﬁc multiplexed PCR ampliﬁcation prior to microarray
ybridization can increase the detection limit of pathogens by a
actor of 100–1000 (Palka-Santini et al., 2009). It is possible that
he sensitivity of the microarray will increase if a targeted mul-
iplexed ampliﬁcation is applied to the samples prior to array
ybridization.
The detection limit for the RSV virus is around 1 TCID50
hen coupled with whole genome ampliﬁcation. This sensitivity
s similar to multiplexed PCR based Luminex assays. A group that
eveloped a Luminex bead assay panel to detect 20 human respi-
atory viruses reported a detection limit of 1 TCID50 for RSV type A
nd 10 TCID50 for RSV type B (Mahony et al., 2007).
Previous evaluation of the original design of this microarray
as demonstrated that the array detected viruses from a variety
f human clinical samples such as urine, feces, serum, skin lesion,
able 5
etection of Adenovirus DNA after 17 hr or 1 hr hybridization on the 72 K LLMDA array.
Adenovirus DNA 0.5 ng 1 ng 
% of adenovirus Gomen strain probes detected at 1 h 10% 30% 
%  of adenovirus Gomen strain probes detected at 17 h 100% 100% 
00 pg to 1 g of adenovirus Gomen DNA was analyzed and the % of probes speciﬁc to ad
ercentage of probes speciﬁc to adenovirus Gomen strain (67 total probes) was  used in th
able 6
LMDA analysis of human fecal samples from acute gastroenteritis cases. The array data w
rray was  also analyzed against viral target sequence database only to conﬁrm the viruses
ere  detected in two  out of two  samples except when noted. A detailed list of target sequ
Sample ID LLMDA viral results Avg
4496 Human calicivirus Hu/NLV/GII/MD145-12/1987/US 207
TT  virus strain TTVCHN1, complete genome 170
4551 Rotavirus A strain S2 genotype
G2P[4] segment 2a
7.5
4912 Human rotavirus A isolate
rj8200/04 NSP4 gene
151
4949  Rotavirus A strain CC598 VP7 geneb 79.2
a Only one out of two replicates detected rotavirus when analyzed against viral only ta
atabase.
b Two of two replicates detected rotavirus A when analyzed against viral only target s
arget  sequences.ons was calculated using the percentage of probes speciﬁc to RSV virus that were
30 RSV speciﬁc probes for each replicate is reported.
cerebral spinal ﬂuid, tracheal aspirate (Erlandsson et al., 2011). In
14 out of 14 clinical samples, the expected virus was detected:
Herpes simplex virus 1, Herpes simplex virus 2, Human papillo-
mavirus 16, Human papillomavirus 6/16/53/61, BK polyomavirus
(BKV), JC polyomavirus, Rotavirus A, Astrovirus, Sapovirus, Dengue
1, Hepatitis C virus in duplicate, enterovirus and RSV. This study
also demonstrated that the microarray detected BK polyomavirus
positive urine samples containing ≥1000 copies/mL (or an equiva-
lent of 5 viral copies in a Phi29-ampliﬁcation reaction) (Erlandsson
et al., 2011). In another study, the array was used to detect Kaposi-
sarcoma associated herpes virus, or human herpes virus 8 from
bladder cancer samples (Paradzˇik et al., 2013). This was  the ﬁrst
indication of the association between herpes virus 8 with bladder
cancer, which further demonstrated the potential of the micro-
bial detection array technology to identify pathogens that might
be linked to cancer and other diseases.
In this study, the performance and sensitivity of the 4-plex ver-
sion of the Lawrence Livermore Microbial Detection Array (LLMDA)
on the detection of viruses was  evaluated using human clinical
samples. In collaboration with the CDC, acute gastroenteritis sam-
ples from the New Vaccine Surveillance Network were applied to
the 4-plex microarray which identiﬁed rotavirus, norovirus and
several enterobacteria (E. coli F11, Salmonella enterica Typhi, Entero-
coccus faecium, Enterococcus faecalis, Bacteriodes intestinalis) from
2 ng 4 ng 8 ng 15.6 ng 125 ng 1000 ng
80% 90% 100% 100% 100% 100%
100% 100% 100% 100% 100% 100%
enovirus was  calculated. Not all concentrations higher than 15.6 ng are shown. The
e calculation.
as analyzed against both viral and bacterial target sequence database. Additionally,
 detected. All samples were performed in duplicate and all viruses or bacteria listed
ences detected is listed in Supplementary ﬁle 2.
 Log odds LLMDA bacterial results Avg Log odds
.6 Salmonella enterica subsp. enterica
serovar Typhi str. CT18
568.3
.0
Escherichia coli F11 677.1
Salmonella enterica subsp. enterica
serovar Typhi str. CT18
79.4
Enterococcus faecium, Glued
fragments of sequence 630811
69.3
Stenotrophomonas maltophilia
K279a
58.7
.7 Escherichia coli F11 807.7
Enterococcus faecalis TX0104 215.2
 Bacteroides
intestinalis DSM 17393
262.8
rget database. Rotavirus was not detected when analyzed using all target sequence
equences. Only one of two replicates detected rotavirus when analyzed against all
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he samples. The NVSN began population-based active gastroen-
eritis surveillance among U.S. children <3 years of age in 2006
Payne et al., 2008, 2011). Current surveillance efforts utilize PCR
nd immunoassays to detect rotavirus and a limited number of viral
athogens, but do not provide a comprehensive analysis of other
nteric pathogens present in samples. The data suggested that bac-
erial and viral co-infections are common in acute gastroenteritis
atients. The virus concentrations in these samples appear to be at
 low level since the human calicivirus was not detected by PCR or
IA. Rotavirus sequences from two samples were detectable only
hen the data was analyzed against viral sequences only. This is
ikely due to the higher level of enteric bacteria concentrations in
he fecal samples. More sensitive viral detection from human fecal
amples could potentially be accomplished using a targeted sample
mpliﬁcation protocol to selectively amplify viral families of inter-
st, which could provide advantages over whole genome random
mpliﬁcation.
The multiplexed pathogen detection array is a useful tool for
apid viral and bacterial pathogen detection. The cost for a 1-plex
icroarray is in the hundreds of dollars per sample, while the cost of
 4-plex microarray is only 25% of the 1-plex array. Though the cost
s probably not going to be at levels comparable to PCR, this assay
an replace hundreds of PCR reactions with just one reaction, there-
ore the 4-plex microarray increases time and efﬁciency in rapid
iagnosis of clinical infections and surveillance of environmental
athogens.
. Conclusion
In an effort to improve cost-effectiveness, speed and through-
ut, a multiplexed version of the Lawrence Livermore Microbial
etection Array was developed and sensitivity testing using a num-
er of viral agents and human clinical samples was performed.
hese results have demonstrated that the array is sensitive to detect
iral infections and have the potential for rapid screening of bac-
erial and viral infections or environmental samples. Multiplexed
icroarrays present a new opportunity for high-throughput and
ost-effective screening of thousands of microbial species. As with
ny technology based on nucleic acid detection, the capabilities
f microarrays are limited by the genome sequence information
vailable at the time of design. Further advances in array technol-
gy such as automated array sample loading and image scanning,
aster hybridization times, and label-free methods to detect probe-
arget binding will broaden the applications of microarrays even
urther. Ultimately, microarrays could be advanced into point-of-
are devices which deliver results in less than an hour.
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